Valuation: Compugen Ltd.

Market Cap 214M 188M 175M 161M 301M 20.42B 306M 2.07B 811M 10.13B 803M 785M 34.99B P/E 2026 *
-7.79x
P/E 2027 * -7.9x
Enterprise Value 214M 188M 175M 161M 301M 20.42B 306M 2.07B 811M 10.13B 803M 785M 34.99B EV / Sales 2026 *
22.7x
EV / Sales 2027 * 13.3x
Free-Float
97.92%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Compugen Ltd.

1 day-5.04%
1 week-9.24%
Current month+5.61%
1 month+8.13%
3 months-17.22%
6 months+15.90%
Current year+47.71%
1 week 2.24
Extreme 2.24
2.4
1 month 2.1
Extreme 2.105
2.56
Current year 1.51
Extreme 1.51
3.24
1 year 1.3
Extreme 1.295
3.24
3 years 0.53
Extreme 0.53
3.24
5 years 0.51
Extreme 0.51
7.48
10 years 0.51
Extreme 0.51
19.9
Manager TitleAgeSince
Chief Executive Officer - 23/09/2025
Director of Finance/CFO 42 15/08/2024
Chief Operating Officer 49 01/01/2024
Director TitleAgeSince
Chairman 59 23/09/2025
Director/Board Member 59 11/06/2018
Director/Board Member 70 11/06/2018
Date Insider Type Main position Quantity % Market Cap.
9/7/26 Fiscal year

Chief Technology Officer

5,625 0.0059%
24/4/26 Fiscal year

Chief Technology Officer

6,000 0.0063%
24/4/26 Fiscal year

Chief Executive Officer

15,000 0.0159%
Change 5-day change 1-year change 3-year change Capi.($)
-5.04%-9.24%+49.67%+101.79% 214M
+0.14%-0.67%-0.88%+11.02% 47.88B
-2.24%+0.31%+393.45%+615.13% 39.09B
+1.40%+3.69%+12.21%+46.79% 36.75B
+13.94%+20.49%+22.85%+7.42% 40.55B
-0.73%+3.38%+4.94%+41.45% 27.96B
+0.40%-0.30% - - 16.77B
-3.12%+7.39%+26.03%+124.08% 15.94B
+2.39%-1.64%+4.74%+9.95% 13.55B
+6.79%+8.17%-4.97%-28.52% 13.81B
Average +1.39%+4.34%+56.45%+103.23% 25.25B
Weighted average by Cap. +2.37%+5.03%+73.27%+125.11%

Financials

2026 *2027 *
Net sales 9.41M 8.26M 7.69M 7.08M 13.27M 899M 13.49M 91.28M 35.73M 446M 35.34M 34.58M 1.54B 16.05M 14.08M 13.11M 12.06M 22.61M 1.53B 23M 156M 60.9M 760M 60.25M 58.95M 2.63B
Net income -27.6M -24.22M -22.55M -20.74M -38.88M -2.64B -39.55M -268M -105M -1.31B -104M -101M -4.52B -28.01M -24.58M -22.89M -21.06M -39.47M -2.68B -40.15M -272M -106M -1.33B -105M -103M -4.59B
Net Debt - -
Logo Compugen Ltd.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Employees
75
Date Price Change Volume
28/07/26 US$2.260 -5.04% 179,048
27/07/26 US$2.380 +4.39% 103,763
24/07/26 US$2.280 -2.56% 200,167
23/07/26 US$2.340 -3.31% 174,536
22/07/26 US$2.420 -2.81% 184,414
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.260USD
Average target price
4.600USD
Spread / Average Target
+103.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CGEN Stock